Stephen Willey
Stock Analyst at Stifel
(4.06)
# 767
Out of 5,182 analysts
134
Total ratings
47.96%
Success rate
13.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stephen Willey
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CELC Celcuity | Maintains: Buy | $115 → $125 | $124.64 | +0.29% | 3 | Mar 26, 2026 | |
| INSM Insmed | Maintains: Buy | $205 → $208 | $159.59 | +30.33% | 9 | Mar 24, 2026 | |
| ZYME Zymeworks | Maintains: Buy | $40 → $47 | $27.35 | +71.85% | 8 | Mar 3, 2026 | |
| ACLX Arcellx | Downgrades: Hold | $127 → $115 | $114.80 | +0.17% | 2 | Feb 24, 2026 | |
| IRON Disc Medicine | Maintains: Buy | $125 → $110 | $67.30 | +63.45% | 2 | Feb 17, 2026 | |
| INCY Incyte | Maintains: Buy | $119 → $120 | $96.96 | +23.76% | 8 | Feb 11, 2026 | |
| EXEL Exelixis | Maintains: Hold | $43 → $44 | $45.41 | -3.11% | 20 | Feb 11, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $33 → $35 | $16.24 | +115.52% | 6 | Jan 29, 2026 | |
| NKTX Nkarta | Maintains: Buy | $12 → $11 | $2.34 | +370.09% | 5 | Nov 11, 2025 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $30 → $9 | $4.07 | +121.13% | 3 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $7 | $3.44 | +103.49% | 7 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $19.10 | +46.60% | 1 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $6 → $5 | $3.44 | +45.35% | 4 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $25 → $20 | $4.51 | +343.46% | 4 | May 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $240 → $100 | $15.60 | +541.03% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.76 | +127.27% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $21.98 | +113.83% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $0.29 | +1,265.65% | 7 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $4 | $2.48 | +61.29% | 1 | Dec 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $53 → $62 | $58.59 | +5.82% | 5 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $5.45 | +65.14% | 1 | Jan 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.51 | +697.34% | 1 | Nov 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $228 → $288 | $1.05 | +27,328.57% | 4 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $21 | $2.78 | +655.40% | 2 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $10 → $4 | $1.76 | +127.27% | 7 | Jul 29, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $125 → $123 | $321.28 | -61.72% | 3 | Aug 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $48 → $47 | $76.43 | -38.51% | 2 | Aug 8, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $102 → $109 | $56.30 | +93.61% | 3 | Aug 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Terminates: Hold | n/a | $24.20 | - | 2 | Jun 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $23 | $7.21 | +219.00% | 5 | Feb 7, 2018 |
Celcuity
Mar 26, 2026
Maintains: Buy
Price Target: $115 → $125
Current: $124.64
Upside: +0.29%
Insmed
Mar 24, 2026
Maintains: Buy
Price Target: $205 → $208
Current: $159.59
Upside: +30.33%
Zymeworks
Mar 3, 2026
Maintains: Buy
Price Target: $40 → $47
Current: $27.35
Upside: +71.85%
Arcellx
Feb 24, 2026
Downgrades: Hold
Price Target: $127 → $115
Current: $114.80
Upside: +0.17%
Disc Medicine
Feb 17, 2026
Maintains: Buy
Price Target: $125 → $110
Current: $67.30
Upside: +63.45%
Incyte
Feb 11, 2026
Maintains: Buy
Price Target: $119 → $120
Current: $96.96
Upside: +23.76%
Exelixis
Feb 11, 2026
Maintains: Hold
Price Target: $43 → $44
Current: $45.41
Upside: -3.11%
Nurix Therapeutics
Jan 29, 2026
Maintains: Buy
Price Target: $33 → $35
Current: $16.24
Upside: +115.52%
Nkarta
Nov 11, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $2.34
Upside: +370.09%
X4 Pharmaceuticals
Aug 29, 2025
Maintains: Buy
Price Target: $30 → $9
Current: $4.07
Upside: +121.13%
Aug 8, 2025
Maintains: Buy
Price Target: $8 → $7
Current: $3.44
Upside: +103.49%
Jun 25, 2025
Initiates: Buy
Price Target: $28
Current: $19.10
Upside: +46.60%
May 14, 2025
Maintains: Hold
Price Target: $6 → $5
Current: $3.44
Upside: +45.35%
May 13, 2025
Maintains: Hold
Price Target: $25 → $20
Current: $4.51
Upside: +343.46%
Mar 21, 2025
Maintains: Buy
Price Target: $240 → $100
Current: $15.60
Upside: +541.03%
Feb 27, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.76
Upside: +127.27%
Oct 8, 2024
Initiates: Buy
Price Target: $47
Current: $21.98
Upside: +113.83%
Aug 20, 2024
Maintains: Buy
Price Target: $8 → $4
Current: $0.29
Upside: +1,265.65%
Dec 19, 2023
Maintains: Buy
Price Target: $3 → $4
Current: $2.48
Upside: +61.29%
Dec 18, 2023
Maintains: Buy
Price Target: $53 → $62
Current: $58.59
Upside: +5.82%
Jan 27, 2023
Initiates: Buy
Price Target: $9
Current: $5.45
Upside: +65.14%
Nov 28, 2022
Initiates: Buy
Price Target: $12
Current: $1.51
Upside: +697.34%
Jun 26, 2020
Downgrades: Hold
Price Target: $228 → $288
Current: $1.05
Upside: +27,328.57%
Mar 17, 2020
Maintains: Buy
Price Target: $22 → $21
Current: $2.78
Upside: +655.40%
Jul 29, 2019
Downgrades: Hold
Price Target: $10 → $4
Current: $1.76
Upside: +127.27%
Aug 13, 2018
Maintains: Buy
Price Target: $125 → $123
Current: $321.28
Upside: -61.72%
Aug 8, 2018
Maintains: Hold
Price Target: $48 → $47
Current: $76.43
Upside: -38.51%
Aug 3, 2018
Maintains: Buy
Price Target: $102 → $109
Current: $56.30
Upside: +93.61%
Jun 25, 2018
Terminates: Hold
Price Target: n/a
Current: $24.20
Upside: -
Feb 7, 2018
Maintains: Buy
Price Target: $20 → $23
Current: $7.21
Upside: +219.00%